Drak2 is not required for tumor surveillance and suppression.
Int Immunol
; 27(3): 161-6, 2015 Mar.
Article
em En
| MEDLINE
| ID: mdl-25568303
ABSTRACT
Drak2 is a promising therapeutic target to treat organ-specific autoimmune diseases such as type 1 diabetes and multiple sclerosis without causing generalized immune suppression. Inhibition of Drak2 may also prevent graft rejection following organ transplantation. However, Drak2 may function as a critical tumor suppressor, which would challenge the prospect of targeting Drak2 for therapeutic treatment. Thus, we examined the susceptibility of Drak2 (-/-) mice in several tumor models. We show that Drak2 is not required to prevent tumor formation in a variety of settings. Therefore, Drak2 does not function as an essential tumor suppressor in in vivo tumor models. These data further validate Drak2 as a viable therapeutic target to treat autoimmune disease and graft rejection. Importantly, these data also indicate that while Drak2 may induce apoptosis when overexpressed in cell lines, it is not an essential tumor suppressor.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sarcoma
/
Transplante de Órgãos
/
Proteínas Serina-Treonina Quinases
/
Diabetes Mellitus Tipo 1
/
Rejeição de Enxerto
/
Vigilância Imunológica
/
Esclerose Múltipla
Tipo de estudo:
Etiology_studies
/
Screening_studies
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article